PPARA and Hepatic fibrosis: In a phase 2 clinical trial, the PPARα/δ dual agonist elafibranor improves lipid metabolism and reduces inflammation, which delays liver fibrosis in non-alcoholic steatohepatitis (NASH) patients (Ratziu et al., 2016).